{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"}],"units":"Participants"}],"description":"Response rates will be estimated as the percentage of patients","groups":[{"description":"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.\n\nCHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.\n\nAUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0.\n\ncyclophosphamide: Given IV\n\netoposide: Given IV\n\niodine I 131 tositumomab: Given IV\n\nquality-of-life assessment: Ancillary study\n\nperipheral blood stem cell transplantation: Undergo ASCT given via central catheter","id":"OG000","title":"Treatment (Radio Labeled Monoclonal Antibody, Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Percentage of patients","reportingStatus":"POSTED","timeFrame":"From date of transplant through date of relapse/progression or death, assessed up to 15 years","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}